The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting
Open accessAbstract
The coronavirus disease 2019 (COVID-19) that is wreaking havoc on worldwide public health and economies has heightened awareness about the lack of effective antiviral treatments for human coronaviruses (CoVs). Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorporation into viral genomes and subsequent disruption of viral replication and fidelity. The development of anti-CoV drugs has long been hindered by the capacity of CoVs to proofread and remove mismatched nucleotides during genome replication and transcription. Here, we review the molecular basis of the CoV proofreading complex and evaluate its potential as a drug target. We also consider existing nucleoside analogs and novel genomic techniques as potential anti-CoV therapeutics that could be used individually or in combination to target the proofreading mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Karaki, S., Benizri, S., Mejías, R., Baylot, V., Branger, N., Nguyen, D. T., Vialet, B., Oumzil, K., Barthélémy, P., & Rocchi, P. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.042 · Cited by 66
Self-citationRetractedCoronaviridae Study Group of the International Committee on Taxonomy of Viruses, Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,403
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105924 · Cited by 6,068
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z.-L. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,515
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Woo, P. C. Y., Lau, S. K. P., Lam, C. S. F., Lau, C. C. Y., Tsang, A. K. L., Lau, J. H. N., Bai, R., Teng, J. L. L., Tsang, C. C. C., Wang, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06540-11 · Cited by 1,677
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., et al. (2020) · Science · doi:10.1126/science.abb7498 · Cited by 1,609
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Bosch, B. J., van der Zee, R., de Haan, C. A. M., & Rottier, P. J. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8801-8811.2003 · Cited by 1,489
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Jordheim, L. P., Durantel, D., Zoulim, F., & Dumontet, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4010 · Cited by 1,211
Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L. M., Guan, Y., Rozanov, M., Spaan, W. J. M., & Gorbalenya, A. E. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00865-9 · Cited by 1,198
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., Leist, S. R., Schäfer, A., Dinnon, K. H., Stevens, L. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5883 · Cited by 1,071
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Beese, L. S., & Steitz, T. A. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07917.x · Cited by 1,048
Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013679 · Cited by 985
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117592 · Cited by 923
Nidovirales: Evolving the largest RNA virus genome
Gorbalenya, A. E., Enjuanes, L., Ziebuhr, J., & Snijder, E. J. (2006) · Virus Research · doi:10.1016/j.virusres.2006.01.017 · Cited by 922
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 887
Chan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2
Thoms, M., Buschauer, R., Ameismeier, M., Koepke, L., Denk, T., Hirschenberger, M., Kratzat, H., Hayn, M., Mackens-Kiani, T., Cheng, J., et al. (2020) · Science · doi:10.1126/science.abc8665 · Cited by 881
Structure of replicating SARS-CoV-2 polymerase
Hillen, H. S., Kokic, G., Farnung, L., Dienemann, C., Tegunov, D., & Cramer, P. (2020) · Nature · doi:10.1038/s41586-020-2368-8 · Cited by 790
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Wang, Q., Wu, J., Wang, H., Gao, Y., Liu, Q., Mu, A., Ji, W., Yan, L., Zhu, Y., Zhu, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.034 · Cited by 776
Morpholino antisense oligomers: the case for an RNase H-independent structural type
Summerton, J. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00150-5 · Cited by 664
Continuous and Discontinuous RNA Synthesis in Coronaviruses
Sola, I., Almazán, F., Zúñiga, S., & Enjuanes, L. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055218 · Cited by 643
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01594 · Cited by 643
Minskaia, E., Hertzig, T., Gorbalenya, A. E., Campanacci, V., Cambillau, C., Canard, B., & Ziebuhr, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508200103 · Cited by 624
History and Recent Advances in Coronavirus Discovery
Kahn, J. S., & McIntosh, K. (2005) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000188166.17324.60 · Cited by 619
FDA-Approved Oligonucleotide Therapies in 2017
Stein, C. A., & Castanotto, D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.023 · Cited by 608
Subissi, L., Posthuma, C. C., Collet, A., Zevenhoven-Dobbe, J. C., Gorbalenya, A. E., Decroly, E., Snijder, E. J., Canard, B., & Imbert, I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323705111 · Cited by 595
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Shiraki, K., & Daikoku, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107512 · Cited by 573
The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing
Snijder, E. J., Decroly, E., & Ziebuhr, J. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.008 · Cited by 558
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Angelini, M. M., Akhlaghpour, M., Neuman, B. W., & Buchmeier, M. J. (2013) · mBio · doi:10.1128/mbio.00524-13 · Cited by 527
Severe Acute Respiratory Syndrome
Hui, D. S. C., & Zumla, A. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.07.001 · Cited by 506
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 501
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Abbott, T. R., Dhamdhere, G., Liu, Y., Lin, X., Goudy, L., Zeng, L., Chemparathy, A., Chmura, S., Heaton, N. S., Debs, R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.020 · Cited by 498
Eckerle, L. D., Becker, M. M., Halpin, R. A., Li, K., Venter, E., Lu, X., Scherbakova, S., Graham, R. L., Baric, R. S., Stockwell, T. B., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000896 · Cited by 491
Conventional and unconventional mechanisms for capping viral mRNA
Decroly, E., Ferron, F., Lescar, J., & Canard, B. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2675 · Cited by 490
Structural basis and functional analysis of the SARS coronavirus nsp14–nsp10 complex
Ma, Y., Wu, L., Shaw, N., Gao, Y., Wang, J., Sun, Y., Lou, Z., Yan, L., Zhang, R., & Rao, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508686112 · Cited by 482
Snijder, E. J., Limpens, R. W. A. L., de Wilde, A. H., de Jong, A. W. M., Zevenhoven-Dobbe, J. C., Maier, H. J., Faas, F. F. G. A., Koster, A. J., & Bárcena, M. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000715 · Cited by 477
Coronaviruses: An RNA proofreading machine regulates replication fidelity and diversity
Denison, M. R., Graham, R. L., Donaldson, E. F., Eckerle, L. D., & Baric, R. S. (2011) · RNA Biology · doi:10.4161/rna.8.2.15013 · Cited by 476
Chen, Y., Cai, H., Pan, J., Xiang, N., Tien, P., Ahola, T., & Guo, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808790106 · Cited by 457
Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 444
In Vitro Reconstitution of SARS-Coronavirus mRNA Cap Methylation
Bouvet, M., Debarnot, C., Imbert, I., Selisko, B., Snijder, E. J., Canard, B., & Decroly, E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000863 · Cited by 406
Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
Ferron, F., Subissi, L., Silveira De Morais, A. T., Le, N. T. T., Sevajol, M., Gluais, L., Decroly, E., Vonrhein, C., Bricogne, G., Canard, B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718806115 · Cited by 404
Global Epidemiology of Bat Coronaviruses
Wong, A. C. P., Li, X., Lau, S. K. P., & Woo, P. C. Y. (2019) · Viruses · doi:10.3390/v11020174 · Cited by 366
Huang, C., Lokugamage, K. G., Rozovics, J. M., Narayanan, K., Semler, B. L., & Makino, S. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002433 · Cited by 352
Shannon, A., Le, N. T.-T., Selisko, B., Eydoux, C., Alvarez, K., Guillemot, J.-C., Decroly, E., Peersen, O., Ferron, F., & Canard, B. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104793 · Cited by 352
Bouvet, M., Imbert, I., Subissi, L., Gluais, L., Canard, B., & Decroly, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201130109 · Cited by 345
The ProTide Prodrug Technology: From the Concept to the Clinic
Mehellou, Y., Rattan, H. S., & Balzarini, J. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00734 · Cited by 345
Structural basis for RNA replication by the hepatitis C virus polymerase
Appleby, T. C., Perry, J. K., Murakami, E., Barauskas, O., Feng, J., Cho, A., Fox, D., Wetmore, D. R., McGrath, M. E., Ray, A. S., et al. (2015) · Science · doi:10.1126/science.1259210 · Cited by 339
Agostini, M. L., Pruijssers, A. J., Chappell, J. D., Gribble, J., Lu, X., Andres, E. L., Bluemling, G. R., Lockwood, M. A., Sheahan, T. P., Sims, A. C., et al. (2019) · Journal of Virology · doi:10.1128/jvi.01348-19 · Cited by 337
High Fidelity of Murine Hepatitis Virus Replication Is Decreased in nsp14 Exoribonuclease Mutants
Eckerle, L. D., Lu, X., Sperry, S. M., Choi, L., & Denison, M. R. (2007) · Journal of Virology · doi:10.1128/jvi.01296-07 · Cited by 332
Egloff, M.-P., Ferron, F., Campanacci, V., Longhi, S., Rancurel, C., Dutartre, H., Snijder, E. J., Gorbalenya, A. E., Cambillau, C., & Canard, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307877101 · Cited by 306
Shannon, A., Selisko, B., Le, N.-T.-T., Huchting, J., Touret, F., Piorkowski, G., Fattorini, V., Ferron, F., Decroly, E., Meier, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18463-z · Cited by 296
de Vries, A. A. F., Horzinek, M. C., Rottier, P. J. M., & de Groot, R. J. (1997) · Seminars in Virology · doi:10.1006/smvy.1997.0104 · Cited by 291
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19
Chien, M., Anderson, T. K., Jockusch, S., Tao, C., Li, X., Kumar, S., Russo, J. J., Kirchdoerfer, R. N., & Ju, J. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00392 · Cited by 286
Ogando, N. S., Zevenhoven-Dobbe, J. C., van der Meer, Y., Bredenbeek, P. J., Posthuma, C. C., & Snijder, E. J. (2020) · Journal of Virology · doi:10.1128/jvi.01246-20 · Cited by 282
Molecular epidemiology, evolution and phylogeny of SARS coronavirus
Luk, H. K. H., Li, X., Fung, J., Lau, S. K. P., & Woo, P. C. Y. (2019) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2019.03.001 · Cited by 280
The coronavirus proofreading exoribonuclease mediates extensive viral recombination
Gribble, J., Stevens, L. J., Agostini, M. L., Anderson-Daniels, J., Chappell, J. D., Lu, X., Pruijssers, A. J., Routh, A. L., & Denison, M. R. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009226 · Cited by 279
A second, non‐canonical RNA‐dependent RNA polymerase in SARS Coronavirus
Imbert, I., Guillemot, J., Bourhis, J., Bussetta, C., Coutard, B., Egloff, M., Ferron, F., Gorbalenya, A. E., & Canard, B. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601368 · Cited by 277
Yates, M. K., & Seley-Radtke, K. L. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2018.11.016 · Cited by 275
Cottam, E. M., Maier, H. J., Manifava, M., Vaux, L. C., Chandra-Schoenfelder, P., Gerner, W., Britton, P., Ktistakis, N. T., & Wileman, T. (2011) · Autophagy · doi:10.4161/auto.7.11.16642 · Cited by 269
Pedersen, N. C., Perron, M., Bannasch, M., Montgomery, E., Murakami, E., Liepnieks, M., & Liu, H. (2019) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x19825701 · Cited by 269
Jin, Z., Smith, L. K., Rajwanshi, V. K., Kim, B., & Deval, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068347 · Cited by 268
Decroly, E., Imbert, I., Coutard, B., Bouvet, M., Selisko, B., Alvarez, K., Gorbalenya, A. E., Snijder, E. J., & Canard, B. (2008) · Journal of Virology · doi:10.1128/jvi.00407-08 · Cited by 252
Coronavirus subgenomic minus-strand RNAs and the potential for mRNA replicons.
Sethna, P. B., Hung, S., & Brian, D. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.14.5626 · Cited by 249
The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent
te Velthuis, A. J. W., Arnold, J. J., Cameron, C. E., van den Worm, S. H. E., & Snijder, E. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp904 · Cited by 240
(1968) · Nature · doi:10.1038/220650b0 · Cited by 238
Coronavirus Nsp10, a Critical Co-factor for Activation of Multiple Replicative Enzymes
Bouvet, M., Lugari, A., Posthuma, C. C., Zevenhoven, J. C., Bernard, S., Betzi, S., Imbert, I., Canard, B., Guillemot, J.-C., Lécine, P., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.577353 · Cited by 227
Xu, X. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg916 · Cited by 224
Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus
Sevajol, M., Subissi, L., Decroly, E., Canard, B., & Imbert, I. (2014) · Virus Research · doi:10.1016/j.virusres.2014.10.008 · Cited by 214
Bhardwaj, K., Guarino, L., & Kao, C. C. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12218-12224.2004 · Cited by 207
SARS-CoV ORF1b-encoded nonstructural proteins 12–16: Replicative enzymes as antiviral targets
Subissi, L., Imbert, I., Ferron, F., Collet, A., Coutard, B., Decroly, E., & Canard, B. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2013.11.006 · Cited by 205
Stuyver, L. J., Whitaker, T., McBrayer, T. R., Hernandez-Santiago, B. I., Lostia, S., Tharnish, P. M., Ramesh, M., Chu, C. K., Jordan, R., Shi, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.244-254.2003 · Cited by 199
Molecular mechanisms of coronavirus RNA capping and methylation
Chen, Y., & Guo, D. (2016) · Virologica Sinica · doi:10.1007/s12250-016-3726-4 · Cited by 197
Nucleoside analogues for the treatment of coronavirus infections
Pruijssers, A. J., & Denison, M. R. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.04.002 · Cited by 196
Urakova, N., Kuznetsova, V., Crossman, D. K., Sokratian, A., Guthrie, D. B., Kolykhalov, A. A., Lockwood, M. A., Natchus, M. G., Crowley, M. R., Painter, G. R., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01965-17 · Cited by 192
Mechanism of Nucleic Acid Unwinding by SARS-CoV Helicase
Adedeji, A. O., Marchand, B., te Velthuis, A. J. W., Snijder, E. J., Weiss, S., Eoff, R. L., Singh, K., & Sarafianos, S. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036521 · Cited by 189
Narayanan, K., Ramirez, S. I., Lokugamage, K. G., & Makino, S. (2015) · Virus Research · doi:10.1016/j.virusres.2014.11.019 · Cited by 187
Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses
Nguyen, T. M., Zhang, Y., & Pandolfi, P. P. (2020) · Cell Research · doi:10.1038/s41422-020-0290-0 · Cited by 185
Pan, J., Peng, X., Gao, Y., Li, Z., Lu, X., Chen, Y., Ishaq, M., Liu, D., DeDiego, M. L., Enjuanes, L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003299 · Cited by 173
Ogando, N. S., Ferron, F., Decroly, E., Canard, B., Posthuma, C. C., & Snijder, E. J. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01813 · Cited by 158
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Driouich, J.-S., Cochin, M., Lingas, G., Moureau, G., Touret, F., Petit, P.-R., Piorkowski, G., Barthélémy, K., Laprie, C., Coutard, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21992-w · Cited by 158
Seybert, A., Hegyi, A., Siddell, S. G., & Ziebuhr, J. (2000) · RNA · doi:10.1017/s1355838200000728 · Cited by 155
RNA-RNA and RNA-protein interactions in coronavirus replication and transcription
Sola, I., Mateos‐Gómez, P. A., Almazán, F., Zúñiga, S., & Enjuanes, L. (2011) · RNA Biology · doi:10.4161/rna.8.2.14991 · Cited by 152
Barnard, D. L., Hubbard, V. D., Burton, J., Smee, D. F., Morrey, J. D., Otto, M. J., & Sidwell, R. W. (2004) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020401500102 · Cited by 150
Comparative analysis of RNA genomes of mouse hepatitis viruses
Lai, M. M. C., & Stohlman, S. A. (1981) · Journal of Virology · doi:10.1128/jvi.38.2.661-670.1981 · Cited by 146
Nucleosides for the treatment of respiratory RNA virus infections
Jordan, P. C., Stevens, S., & Deval, J. (2018) · Antiviral chemistry & chemotherapy · doi:10.1177/2040206618764483 · Cited by 145
A planarian nidovirus expands the limits of RNA genome size
Saberi, A., Gulyaeva, A. A., Brubacher, J. L., Newmark, P. A., & Gorbalenya, A. E. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007314 · Cited by 144
Bécares, M., Pascual‐Iglesias, A., Nogales, A., Sola, I., Enjuanes, L., & Zúñiga, S. (2016) · Journal of Virology · doi:10.1128/jvi.03259-15 · Cited by 138
Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle
Pyrć, K., Bosch, B., Berkhout, B., Jebbink, M. F., Dijkman, R., Rottier, P. J. M., & van der Hoek, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01598-05 · Cited by 131
Antiviral Agents Acting as DNA or RNA Chain Terminators
Clercq, E. D., & Neyts, J. H. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-79086-0_3 · Cited by 128
Nucleotide analogues as inhibitors of SARS‐CoV Polymerase
Ju, J., Li, X., Kumar, S., Jockusch, S., Chien, M., Tao, C., Morozova, I., Kalachikov, S. M., Kirchdoerfer, R. N., & Russo, J. J. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.674 · Cited by 127
The cellular and molecular pathogenesis of coronaviruses.
Compton, S. R., Barthold, S. W., & Smith, A. L. (1993) · PubMed · Cited by 121
Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important?
Wong, G., Bi, Y., Wang, Q.-H., Chen, X.-W., Zhang, Z., & Yao, Y. (2020) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.031 · Cited by 114
Neuman, B. W., Stein, D. A., Kroeker, A. D., Churchill, M., Kim, A., Kühn, P., Dawson, P. E., Moulton, H. M., Bestwick, R. K., Iversen, P. L., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9665-9676.2005 · Cited by 108
Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds
Nan, Y., & Zhang, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00750 · Cited by 108
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
Jácome, R., Campillo-Balderas, J. A., de León, S. P., Becerra, A., & Lazcano, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-66440-9 · Cited by 104
Simeprevir Potently Suppresses SARS-CoV‑2 Replication and Synergizes with Remdesivir
Lo, H. S., Hui, K. P. Y., Lai, H. M., He, X., Khan, K. S., Kaur, S., Huang, J., Li, Z., Chan, A., Cheung, H. H.-Y., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01186 · Cited by 104
Self-citationDeval, J. (2009) · Drugs · doi:10.2165/00003495-200969020-00002 · Cited by 86
Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice
Crosby, J. R., Zhao, C., Jiang, C., Bai, D., Katz, M., Greenlee, S., Kawabe, H., McCaleb, M. L., Rotin, D., Guo, S., et al. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.05.003 · Cited by 86
Neuman, B. W., Stein, D. A., Kroeker, A. D., Paulino, A., Moulton, H. M., Iversen, P. L., & Buchmeier, M. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5891-5899.2004 · Cited by 75
Case, J. B., Ashbrook, A. W., Dermody, T. S., & Denison, M. R. (2016) · Journal of Virology · doi:10.1128/jvi.00542-16 · Cited by 74
Islands as Hotspots for Emerging Mosquito-Borne Viruses: A One-Health Perspective
Mavian, C. N., Dulcey, M., Munoz, O. S., Salemi, M., Vittor, A. Y., & Capua, I. (2018) · Viruses · doi:10.3390/v11010011 · Cited by 70
Addressing the selectivity and toxicity of antiviral nucleosides
Feng, J. Y. (2018) · Antiviral chemistry & chemotherapy · doi:10.1177/2040206618758524 · Cited by 64
Biochemical Characterization of Exoribonuclease Encoded by SARS Coronavirus
Chen, P., Jiang, M., Hu, T., Liu, Q., Chen, X. S., & Guo, D. (2007) · BMB Reports · doi:10.5483/bmbrep.2007.40.5.649 · Cited by 61
Implications of altered replication fidelity on the evolution and pathogenesis of coronaviruses
Smith, E. C., & Denison, M. R. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.07.005 · Cited by 60
Gabriel, G., Nordmann, A., Stein, D. A., Iversen, P. L., & Klenk, H. (2008) · Journal of General Virology · doi:10.1099/vir.0.83449-0 · Cited by 56
Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold
Perales, C., & Domingo, E. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_459 · Cited by 49
Current prodrug strategies for improving oral absorption of nucleoside analogues
Zhang, Y., Gao, Y., Wen, X., & Ma, H. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.12.006 · Cited by 47
Antisense Oligonucleotides, A Novel Developing Targeting Therapy
Karaki, S., Paris, C., & Rocchi, P. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82105 · Cited by 37
Self-citationDuan, M., Zhou, Z., Lin, R., Yang, J., Xia, X., & Wang, S. (2008) · Antiviral Therapy · doi:10.1177/135965350801300112 · Cited by 34
Nucleoside analogue delivery systems in cancer therapy
Diab, R., Degobert, G., Hamoudeh, M., Dumontet, C., & Fessi, H. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.5.513 · Cited by 26
Cited by
The T cell immune response against SARS-CoV-2
Moss, P. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,235
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460
“Because of the huge number of genome replications that occur in infected populations and error-prone replication, viral mutations do and will continue to occur (Robson et al., 2020).”
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 453
Metadata
- Authors
- Robson, F., Khan, K. S., Le, T. K., Paris, C., Demirbag, S., Barfuss, P., Rocchi, P., & Ng, W.-L.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 79
- Issue
- 5
- Pages
- 710-727
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W3046843764
- Cited by
- 396
- References
- 123
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.